Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 163

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement

Open access
Johnson, Douglas B., Nixon, Mellissa J., Wang, Yu, Wang, Daniel Y., Castellanos, Emily, Estrada, Monica V., Ericsson-Gonzalez, Paula I., Cote, Candace H., Salgado, Roberto, Sanchez, Violeta, Dean, Phillip T., Opalenik, Susan R., Schreeder, Daniel M., Rimm, David L., Kim, Ju Young, Bordeaux, Jennifer, Loi, Sherene, Horn, Leora, Sanders, Melinda E., Ferrell, P. Brent, Xu, Yaomin, Sosman, Jeffrey A., Davis, Randall S., Balko, Justin M.·2018·JCI Insight

Abstract

Immunotherapies targeting the PD-1 pathway produce durable responses in many cancers, but the tumor-intrinsic factors governing response and resistance are largely unknown. MHC-II expression on tumor cells can predict response to anti-PD-1 therapy. We therefore sought to determine how MHC-II expression by tumor cells promotes PD-1 dependency. Using transcriptional profiling of anti-PD-1-treated patients, we identified unique patterns of immune activation in MHC-II+ tumors. In patients and preclinical models, MHC-II+ tumors recruited CD4+ T cells and developed dependency on PD-1 as well as Lag-3 (an MHC-II inhibitory receptor), which was upregulated in MHC-II+ tumors at acquired resistance to anti-PD-1. Finally, we identify enhanced expression of FCRL6, another MHC-II receptor expressed on NK and T cells, in the microenvironment of MHC-II+ tumors. We ascribe this to what we believe to be a novel inhibitory function of FCRL6 engagement, identifying it as an immunotherapy target. These data suggest a MHC-II-mediated context-dependent mechanism of adaptive resistance to PD-1-targeting immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci.insight.120360

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 163

Metadata

Authors
Johnson, D. B., Nixon, M. J., Wang, Y., Wang, D. Y., Castellanos, E., Estrada, M. V., Ericsson-Gonzalez, P. I., Cote, C. H., Salgado, R., Sanchez, V., Dean, P. T., Opalenik, S. R., Schreeder, D. M., Rimm, D. L., Kim, J. Y., Bordeaux, J., Loi, S., Horn, L., Sanders, M. E., Ferrell, P. B., Xu, Y., Sosman, J. A., Davis, R. S., & Balko, J. M.
Venue
JCI Insight
Published
2018-12-20
Volume
3
Issue
24
ISSN
2379-3708 (ISSN-L)
OpenAlex
W2904276001
Cited by
163
References
11
FWCI
4.97
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement. https://app.cochat.ai/papers/10.1172/jci.insight.120360
The paper
Johnson, D. B., Nixon, M. J., Wang, Y., Wang, D. Y., Castellanos, E., Estrada, M. V., Ericsson-Gonzalez, P. I., Cote, C. H., Salgado, R., Sanchez, V., Dean, P. T., Opalenik, S. R., Schreeder, D. M., Rimm, D. L., Kim, J. Y., Bordeaux, J., Loi, S., Horn, L., Sanders, M. E., . . . Balko, J. M. (2018). Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement. JCI Insight. https://doi.org/10.1172/jci.insight.120360

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.